Pharmaceutical research.
Publisher:
Thieme,. New York, NY : Kluwer Academic/Plenum Publishers (1999)
Frequency: Monthly
Country: United States
Language: English
Start Year:1984 -
ISSN:
0724-8741 (Print)
1573-904X (Electronic)
0724-8741 (Linking)
1573-904X (Electronic)
0724-8741 (Linking)
Impact Factor
3.7
2022
| NLM ID: | 8406521 |
| (DNLM): | P10510000(s) |
| (OCoLC): | 09679417 |
| Coden: | PHREEB |
| Classification: | W1 PH167H |
A nebulized gelatin nanoparticle-based CpG formulation is effective in immunotherapy of allergic horses. In the recent years, nanotechnology has boosted the development of potential drug delivery systems and material engineering on nanoscale basis in order to increase drug specificity and reduce side effects. A potential delivery system for immunostimulating agents such as cytosine-phosphate-guanine-oligodeoxynucleotides (CpG-ODN) needs to be developed to maximize the efficacy of immunotherapy against hypersensitivity. In this study, an aerosol formulation of biodegradable, biocompatible and nontoxic gelatin nanoparticle-bound CpG-ODN 2216 was used to treat equine recurrent airway obstruction in ...
The pharmacokinetics of the weakly protein-bound anionic compound diatrizoate in serum and synovial fluid of the horse. To establish a pharmacokinetic model for the model drug, sodium diatrizoate (DTZ), allowing joint disappearance kinetics to be estimated from serum appearance kinetics following intra-articular administration, and to calculate the relative joint exposure after intravenous and intra-articular DTZ administration (F(iv/IA)). Methods: Each of five horses received an aqueous solution of 3.9 mg/kg sodium diatrizoate both intravenously and intra-articularly separated by a one-week wash out period. Serum and synovial samples were collected over 7 h and analyzed for content of model compound using indu...